Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis

Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis


Authors:
Catherine M. Ludwig,  Jennifer L. Hsiao, Peter A. Lio, and Vivian Y. Shi

Abstract:
Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity.

Transitioning to dupilumab should be executed strategically tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.

Comentarios

Entradas populares de este blog

Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of Departments of Dermatology; Network of Anaphylaxis; and Department of Dermatology, University Hospital Erlangen, Germany)

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).